BCR-ABL BREAKPOINT ANALYSIS,QUALITATIVE PCR

The BCR-ABL Breakpoint Analysis (Qualitative PCR) is a molecular blood test that detects the presence of the BCR‑ABL fusion transcript (Philadelphia chromosome) associated with chronic myeloid leukemia and certain acute leukemias. This sensitive, home‑collected PCR assay identifies whether BCR‑ABL transcripts and common breakpoint variants are present, providing critical information for initial diagnosis, selection of targeted tyrosine‑kinase inhibitor therapy, and early detection of molecular relapse. It is recommended for patients with suspected or known CML for baseline assessment and ongoing monitoring, with trained sample collection at home across Dubai and the UAE and specialist interpretation to guide timely clinical decisions.

• BCR-ABL fusion (qualitative): Positive / Negative
• e13a2 (b2a2) transcript — p210
• e14a2 (b3a2) transcript — p210
• e1a2 transcript — p190

• Qualitative PCR detection of BCR-ABL fusion transcript (Philadelphia chromosome) from peripheral blood
• Home phlebotomy collection with secure specimen transport across Dubai and the UAE
• Supports diagnostic confirmation and molecular monitoring for CML and Philadelphia‑positive ALL
• Results delivered to the patient and treating clinician to guide targeted therapy decisions
• Performed in an accredited molecular diagnostics laboratory using clinically validated methods

• Home blood collection for qualitative PCR detection of BCR-ABL (Philadelphia chromosome) fusion transcripts
• Sensitive qualitative assay to confirm presence or absence of BCR-ABL for informed diagnostic and treatment decisions
• Useful for therapy monitoring to detect molecular relapse or persistent disease (presence vs. non-detection)
• Available across Dubai and the UAE with accredited laboratory processing and secure result delivery to you and your clinician
• Typically rapid reporting (usually within 48–72 hours) with clear, clinically actionable results compliant with UAE standards

• Home venous blood collection by trained phlebotomists across Dubai and the UAE
• Qualitative PCR detection of BCR-ABL fusion transcripts, including common breakpoints (e13a2/e14a2) — presence/absence result
• Intended for diagnostic confirmation and relapse detection to support timely treatment decisions (not a quantitative molecular load test)
• Processed in an accredited UAE laboratory with secure electronic report delivery to you and your treating physician